HR 9699 United States House · 119th Congress

Drug Deal Disclosure Act

The Drug Deal Disclosure Act requires the Department of Health and Human Services to publicly release records of specific agreements between the federal government and major drug manufacturers starting in 2025. These agreements must include provisions such as offering lower drug prices based on international rates, providing discounts through government platforms like TrumpRx, or receiving special exemptions from import duties and regulatory reviews. While the bill mandates that most documents be made available in a searchable format, it allows the government to withhold only specific confidential pricing details if legally required by foreign laws or court orders, provided a justification is published. Additionally, the law directs the Congressional Budget Office and the Government Accountability Office to analyze the economic and budgetary impacts of these deals, including effects on Medicare, Medicaid, and drug competition.
Bill status in committee 1 of 4 stages cleared
Introduction
Jul 2026
Committee Review
Floor Vote
President
Introduced Jul 15, 2026 Last action Jul 15, 2026
Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
2
Key actions
0
Committee
1
Jul 15, 2026
Committee
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
lower
Jul 15, 2026
Introduced
Introduced in House
lower
1 primary · 24 co-sponsors

Sponsors